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Background/Purpose: We analyzed complications and functional outcomes and
aimed at identifying prognostic factors for functional outcomes and complications in
patients who underwent salvage total laryngectomy (STL) for residual, recurrent, and
second primary squamous cell carcinoma (SCC) of the larynx and hypopharynx after
initial (chemo)radiation.
Methods: Retrospective cohort study of patients who underwent STL in four major
Belgian reference hospitals between 2002 and 2018. Prognostic factors for functional
outcomes and complications were identified with uni- and multivariable analysis.
Results: A total of 405 patients were included in the final analysis. STL was
performed for residual tumor (40.2%), local recurrence (40.5%), or second primary
laryngeal or hypopharyngeal SCC (19.4%). Early postoperative complications were
experienced by 34.2% of patients: postoperative hemorrhage occurred in 5.4%, wound
infection in 16.2%, and clinical pharyngocutaneous fistula (PCF) in 25.5% of patients.
Early readmission proved necessary in 15.1% of cases, most often due to late PCF
development (72.2%). Patients achieved total peroral intake in 94.2% of cases. However,
subjective dysphagia was reported by 31.3% of patients during follow-up. Functional
speech, defined as functional communication by speech without additional aids, was
reported in 86.7% of cases and was most often achieved by tracheo-esophageal
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puncture (TEP) (94.1%). In a multivariable model, lower preoperative hemoglobin (<12.5
g/dl) was identified as an independent prognostic factor for higher overall complication
rate. No risk factors were found significant for clinical fistula formation. Vascularized
tissue augmentation did not significantly prevent clinical PCF. Patients with positive
section margins, patients initially treated with surgery combined with adjuvant RT
(vs. radiotherapy alone), and those developing PCF after STL were less likely to
achieve total peroral intake. Postoperative dysphagia proved more likely in patients who
developed a PCF postoperatively, and less likely in patients who underwent STL without
partial pharyngectomy and in patients with myocutaneous pectoralis major (PM) flap
reconstruction, compared to muscle onlay PM flap. Achieving postoperative functional
speech proved most likely in patients with smaller tumors (lower pT classification) and
free section margins.
Conclusion: Substantial complication rates and favorable functional outcomes are
reported after STL.
Keywords: complications, functional outcomes, hypopharynx, larynx, recurrence, salvage surgery, squamous cell
carcinoma, total laryngectomy
INTRODUCTION
The management of advanced hypopharyngeal and laryngeal
cancers has seen drastic changes over the last decades. The
Veterans Affairs (VA) trial in 1991 followed by the Radiation
Therapy Oncology Group (RTOG) 91–11 trial in 2003 showed
similar survival rates between organ preservation therapy and
total laryngectomy (TL) for advanced laryngeal cancers (1–
3). These comparable oncologic outcomes, combined with a
high probability of preserving speech and swallowing functions,
made radiotherapy (RT), and chemoradiotherapy (CRT) the
standard of care to treat laryngeal and hypopharyngeal cancers
in many institutions (4–7). However, on the long term,
radiation-based therapy also has the potential to compromise
these functions due to permanent tissue damage (RT-induced
fibrosis and xerostomia) (8). In 21–66% of patients who are
primarily treated with organ preservation strategies, salvage total
laryngectomy (STL) eventually proves necessary when tumor
recurrence occurs or residual cancer is diagnosed following
RT/CRT (9, 10). However, STL carries a higher complication
risk when compared to primary laryngectomy in a non-
irradiated patient. Radiation affects the tissue’s microvasculature;
more precisely, it causes subintimal fibrosis, endarteritis, and
thrombus formation, inducing a hypovascular, hypocellular, and
hypoxic environment, which in turn results in worse healing
conditions (11). Pharyngocutaneous fistula (PCF), an abnormal
communication between the digestive tract and the cervical
skin or tracheostoma resulting in salivary leakage, is the most
common major wound complication after STL (12–14). PCF is
associated with prolonged hospitalization, the potential need for
Abbreviations: Std, Standard deviation; IQR, Interquartile range; CRT,
Chemoradiation therapy; RT, Radiation therapy; PM, Pectoralis major; MRND,
Modified radical neck dissection; STL, Salvage total laryngectomy; TEP, Tracheo-
esophageal puncture; OR, Odds ratio; CI, Confidence interval; TL, Subgroup total
laryngectomy; RE, Relative effect.
surgical revisions, and it delays initiation of peroral feeding and
(re-)irradiation when indicated. Moreover, PCF can potentially
lead to death due to carotid blowout (12–14). A recent systematic
review of 49 studies investigating complications following STL
reported an overall complication rate of 67.5%, with a pooled
incidence of 28.9% (95% CI 25.5–32.5%) of patients developing
a PCF (14). Multiple risk factors have been linked with a
higher PCF and complication rate after STL, but results are not
consistent across studies (14). Factors reported to predispose to
PCF include preoperative (chemo)radiotherapy, types of surgery,
neck dissection, pharyngeal closure techniques, positive tumor
margins, presence of a preoperative tracheotomy, comorbidities,
tumor site and stage, nutrition status, and hemoglobin levels (14–
16). The aim of this multicenter retrospective cohort study is
to report and analyze functional outcomes and complications
after STL and identify prognostic factors for functional outcome
and complications.
PATIENTS AND METHODS
Ethical Considerations
The current study was approved by and carried out in accordance
with the recommendations of the Coordinating Institutional
Review Board (University Hospital Leuven Committee for
Medical Ethics) and the local Ethical boards of participating
centers. Informed consent was waived given the retrospective
nature of this study (study registration numbers S61749
and B670201938931).
Patients
We conducted a multicentric retrospective cohort study of all
patients who underwent STL for squamous cell carcinoma (SCC)
of the larynx or hypopharynx in a 16-year period from 01.01.2002
to 31.12.2018. Hospitals who participated in this study were two
academic centers (UZ Leuven, and UZ Ghent) and two major
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regional centers (AZ Sint-Jan in Bruges, AZ Sint-Lucas in Ghent).
A total of 405 patients were identified and included in this
retrospective review upon screening of hospital databases.
Predefined inclusion criteria were as follows:
– STL with or without partial pharyngectomy for local recurrent
(diagnosis >12 months and <60 months after primary
treatment) or residual (diagnosis <12 months after primary
treatment) SCC of a laryngeal or hypopharyngeal tumor
primarily treated with CRT or RT.
– STL with or without partial pharyngectomy for second
primary SCC in an irradiated larynx or hypopharynx after
primary treatment with RT or CRT. According to the
criteria of Warren and Gates and its modification by
the National Cancer Institute, second primary SCC was
defined as a metachronous or synchronous tumor evolving
from a different anatomical subsite as the primary tumor,
or as a synchronous tumor in the same subsite as the
primary tumor but developing later than 60 months after
diagnosis of the primary tumor (17–19). As such, local
recurrence of a laryngeal/hypopharyngeal tumor after initial
(chemo)radiation was defined as malignancy in the same
laryngeal/hypopharyngeal subsite as the primary tumor
diagnosed within 60 months after the diagnosis of the
first malignancy.
Predefined exclusion criteria were as follows:
– STL performed for non-squamous cell carcinomas
– Patients who underwent STL with circumferential (total)
pharyngectomy requiring reconstruction with free jejunal
transfer, gastric pull-up procedure (gastric transposition),
colon interposition, or tubed/tunneled(myo)cutaneous flaps
(e.g., anterolateral thigh, radial forearm flap, latissimus dorsi,
myocutaneous pectoralis major)
– Patients who underwent a “functional” laryngectomy [e.g.,
for persistent aspiration after primary radio(chemo)therapy
without evidence for recurrent or residual malignancy]
Data
The medical records of 405 patients were retrospectively
reviewed. The data related to patient, tumor, and treatment and
complications as well as functional outcomes were retrieved
from the patient’s health records. All data were pseudonymized
in the participating centers and eventually gathered in one
central database with the University Hospitals Leuven as data-
controller. Tumor staging was reviewed according to the most
recent 8th edition of the UICC/AJCC TNM classification. The
reference limits of biomarkers were chosen according to limits
suggested in previous studies and general accepted normality
ranges, in which anemia was defined as hemoglobin (Hb)
<12.5 g/dl and hypoalbuminemia as albumin (Ab) < 3.5 g/dl
(16, 20–22). PCF was defined as an abnormal communication
between the digestive tract/neopharynx and the cervical skin
and/or tracheostoma resulting in a clinically visible salivary
leakage. Postoperative hemorrhage was defined as postoperative
bleeding that required surgical revision. Postoperative wound
infection was defined as a local wound infection with or without
abcedation that required the administration of antibiotics
outside of the routine postoperative antibiotics administration
and/or surgical drainage. Various variables were assessed as
potential prognostic factors for complication rate, as well as for
“overall complication rate” as for PCF specifically (Table 1).
We also examined the relationship between the results of
the postoperative upper gastrointestinal tract radiograph
(esophagram/esophageal fluoroscopy) with aqueous low osmolar
non-ionic iodine contrast (Ultravist R© or iopromide) and
clinical PCF formation. Functional outcomes assessed were
time to resume oral feeding, achievement of total peroral
intake, achievement of functional speech, presence (or absence)
of postoperative permanent tube feeding, and postoperative
dysphagia. Functional speech was defined as functional
communication by speech [esophageal speech, electrolarynx
speech, and trachea-esophageal puncture (TEP) speech]
without the need for additional aids (e.g., writing, gestures, etc.).
Dysphagia was defined as a sense of obstruction while swallowing
with/without signs of regurgitation, mentioned in medical files,
with or without objective confirmation of a neopharyngeal
stenosis on esophagram or gastroscopy/esophagoscopy.
Variables analyzed as potential risk factors for functional
outcomes were type of salvage operation (TL vs. TL with partial
pharyngectomy), reconstruction type [pectoralis major (PM)
flap muscle onlay vs. myocutaneous PM flap vs. none], treatment
type of the first tumor (surgery and adjuvant RT vs. surgery
and adjuvant CRT vs. definitive CRT vs. definitive RT), type
of secondary tumor (local recurrence vs. residual tumor vs.
second primary), total RT dose at the level of the larynx during
previous treatment, tracheo-esophageal puncture (primary vs.
secondary vs. none), postoperative complications (any type),
postoperative clinical PCF formation, adjuvant treatment after
STL, and margin status (free vs. close vs. positive).
Treatment
STL was performed in all centers according to a standardized and
well-described surgical technique (23). Surgical details differed
between centers: after resection of the larynx or laryngopharynx,
a myotomy of the cricopharyngeal muscle was performed in
all cases; pharyngeal closure was performed with interrupted or
running (depending on the center) absorbable sutures in a T-
fashion in two layers (mucosa and submucosa) or three layers
(mucosa, submucosa, and constrictor muscle, depending on the
center); neurectomy of the pharyngeal plexus was omitted. The
tracheostoma was created by suturing the cartilaginous trachea
to the caudal skin flap, while the membranous trachea was
sutured to the cranial skin flap. Neck dissections were always
performed when a cN+ neck was present. However, the decisions
to perform elective neck dissections of the lateral compartment,
thyroidectomy (non, partial or complete), and reconstruction
(PM onlay, PM myocutaneous inset or primary closure) were
left at the surgeon’s discretion and depended on institutional
practice. Central neck dissection was always performed and
varied from a formal bilateral level VI and VII dissection to
more limited dissection of trachea-esophageal nodes, depending
on the institution, surgeon, and pathology. All patients received
per- and postoperatively intravenous prophylactic antibiotic
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TABLE 1 | Factors associated with overall complications and PCF formation (univariable).
Variables Postoperative complications PCF
OR 95% CI (p) OR 95% CI (p)
Preoperative Hb
≥12.5 g/dl vs. <12.5 g/dl
0.579 0.360–0.931 (0.0241) 0.820 0.489–1.373 (0.4495)
Postoperative Hb
≥12.5 g/dl vs. <12.5 g/dl
0.442 0.241–0.812 (0.0085) 0.516 0.263–1.014 (0.0550)
Preoperative albumin
≥3.5 g/dl vs. <3.5 g/dl 1.584 0.654–3.837 (0.3079) 1.062 0.419–2.693 (0.8999)
Postoperative albumin
≥3.5 g/dl vs. <3.5 g/dl 0.630 0.259–1.533 (0.3090) 0.358 0.115–1.117 (0.0769)
Preoperative tracheotomy
Yes vs. No 1.868 0.942–3.706 (0.0737) 1.896 0.931–3.864 (0.0780)
Preoperative active smoking
Yes vs. No 0.907 0.556–1.479 (0.6957) 0.960 0.561–1.644 (0.8824)
Type of salvage operation
STL+partial pharyngectomy vs. STL 1.506 0.958–2.369 (0.0761) 1.147 0.707–1.861 (0.5793)
Reconstruction type
PM flap muscle onlay vs. myocutaneous PM flap 0.678 0.388–1.182 (0.1705) 0.902 0.486–1.674 (0.7440)
PM flap muscle onlay vs. none 0.895 0.546–1.467 (0.6596) 0.800 0.470–1.363 (0.4116)
myocutaneous PM flap vs. none 1.321 0.783–2.228 (0.2971) 0.887 0.499–1.576 (0.6827)
Type of second tumor
Local recurrence vs. Residual tumor 0.841 0.526–1.347 (0.4721) 0.618 0.368–1.038 (0.0687)
Local recurrence vs. Second primary 0.778 0.437–1.383 (0.3921) 0.717 0.377–1.361 (0.3091)
Residual tumor vs. Second primary 0.924 0.523–1.634 (0.7868) 1.160 0.627–2.147 (0.6357)
Treatment initial tumor (residual/recurrent)*
Surgery + adjuvant RT vs. definitive CRT 0.873 0.208–3.670 (0.8527) 1.829 0.426–7.851 (0.4169)
Surgery + adjuvant RT vs. definitive RT 1.813 0.474–6.943 (0.3849) 2.522 0.656–9.699 (0.1783)
Surgery + adjuvant RT vs. surgery + adjuvant CRT 2.400 0.175–32.868 (0.5122)
Definitive CRT vs. definitive RT 2.078 1.097– 3.937 (0.0249) 1.379 0.690–2.758 (0.3631)
Definitive CRT vs. surgery + adjuvant CRT 2.749 0.266–28.423 (0.3961)
Definitive RT vs. surgery + adjuvant CRT 1.323 0.135–12.927 (0.8097)
Treatment initial tumor (second primary)*
Surgery + adjuvant RT vs. definitive CRT 0.563 0.090–3.518 (0.5385) 0.562 0.090–3.518 (0.5385)
Surgery + adjuvant RT vs. definitive RT 0.619 0.147–2.608 (0.5130) 1.281 0.293–5.598 (0.7418)
Definitive CRT vs. definitive RT 1.100 0.276–4.380 (0.8925) 2.278 0.551–9.417 (0.2556)
Radiotherapy initial tumor dose on larynx (Gray)
+1 unit 0.993 0.960–1.026 (0.6632) 0.982 0.948–1.017 (0.3032)
Extent of neck dissection
Bilateral vs. Ipsilateral 0.754 0.458–1.240 (0.2653) 0.597 0.342–1.043 (0.0699)
Bilateral vs. None 1.001 0.591–1.695 (0.9975) 0.651 0.364–1.162 (0.1466)
Ipsilateral vs. None 1.328 0.786–2.243 (0.2888) 1.089 0.627–1.892 (0.7620)
Tracheo-oesofageal puncture
Secondary/none vs. Primary 1.505 0.800–2.831 (0.2053) 1.463 0.749–2.858 (0.2658)
Treating center, global test - - (0.0463) - - (0.1640)
Treating center, global test, after correction for confounders - - (0.1904) - - (0.1821)
Continuous variables: OR > (<)1: increased (decreased) risk with increasing variable level.
Binary variables/pairwise tests: OR > (<)1: higher (lower) risk for first category. Reconstruction type: radial forearm free flap (n = 3) and other (n = 1) excluded.
*Not all pairwise comparisons were estimable due to small groups/zero events.
Bold values are statistically significant (p < 0.05).
treatment with cephazolin + metronidazole or amoxicillin +
clavulanic acid for 2 days. On the 10th postoperative day,
all patients underwent an esophagram, except when a clinical
PCF was present. If the esophagram did not show signs of
PCF formations, peroral feeding was initiated the following
day with liquid and semiliquid foods. In the case of a clinical
PCF or an esophagram showing (subclinical) fistula, peroral
feeding was postponed until subsequent esophagrams (5–7 days
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after the prior) suggested complete healing of the PCF tract.
Most frequently, PCFs were managed conservatively (nil per
os, cuffed tracheostomy tube in case of PCF draining in the
tracheostoma). Surgical interventions to close the PCF (e.g.,
with PM of free flaps) were considered when conservative
measures failed or when fistula trajectories were judged unlikely
to heal with conservative measures alone, or when evolution
to serious complications (e.g., carotid blowout) was suspected.
Postoperative care, including feeding management, antibiotics,
and imaging, were uniform among centers. Adjuvant therapy
(e.g., re-irradiation) after STL was performed according to the
consensus of the multidisciplinary hospital’s tumor board.
Statistical Analysis
Logistic regression models were used to analyze prognostic
effects of patient or treatment characteristics on binary
outcomes, including complications or functional outcomes and
re-admission. Results are presented as odds ratios (OR) with 95%
confidence intervals. A forward selection procedure was used for
the selection of a multivariable model of independent prognostic
variables for complications or functional outcomes, with a 5%
significance level for entering variables. Linear regression models
were used to analyze prognostic effects of patient or treatment
characteristics on hospital stay. Analyses were performed on
a log-transformed outcome variable. Results are presented as
relative effects (RE) with 95% confidence intervals. A backward
selection procedure was used for the selection of a multivariable
model of independent prognostic variables for hospital stay,
with a 5% significance level for removal of variables. All tests
are two-sided, and a 5% significance level was assumed for all
tests. No corrections for multiplicity were performed due to the
explorative nature of the study. Analyses have been performed
using SAS software (version 9.4 of the SAS System forWindows).
Follow-up summary statistics were based on the Kaplan–Meier
estimate of potential follow-up (24).
RESULTS
Patient Characteristics
This cohort study included 405 patients, consisting of 378 males
(93.3%) and 27 females (6.7%), with a mean age of 65.3 years (SD
9.8 years, range 40.3–91.2 years). At the time of diagnosis of the
initial tumor, 76.9 % (n = 279) and 29.0% (n = 99) of patients
were active smokers and active heavy drinkers, respectively.
A substantial amount of patients (n = 106, 30.6%) still
smoked at the time of diagnosis of the recurrent/residual/second
primary tumor. Thirty-eight patients (10.4%) were tracheotomy-
dependent before surgery. The complete patient characteristics
are summarized in Table 2.
Tumor Characteristics
Initial tumor characteristics are shown in Table 3. Primary
tumors were almost exclusively squamous cell carcinomas
(99.3%) and were most frequently located in the glottis (n= 260;
64.7%). Most initial tumors were considered as locoregionally
limited disease (cT1 and cT2 in 41.4 and 31.4% of cases, cN0 in
81.6% of cases). Stage I (n = 160; 39.9%) was the most common
overall stage. In this group of primary tumors, 308 patients
TABLE 2 | Patient characteristics.
Patient
characteristics
n %
Gender (n = 405)
Male 378 93.33
Female 27 6.67
Age at time of diagnosis recurrent/second primary tumor
N 395
Mean 65.31
Std 9.809
Median 65.37
IQR (57.82–71.92)
Range (40.28–91.24)
Preoperative active smoking (n = 347)
No 241 69.45
Yes 106 30.55
Active smoking at time of diagnosis (n = 363) at the time of diagnosis of
the initial tumor
No 84 23.14
Yes 279 76.86
Active drinking at time of diagnosis (n = 341) at the time of diagnosis of
the initial tumor
No 242 70.97
Yes 99 29.03
Preoperative tracheotomy (n = 366)
No 328 89.62
Yes 38 10.38
(76.4%) were treated with RT alone. Table 4 shows secondary
tumor characteristics. Mean time between treatment of the first
tumor and the diagnosis of the second tumor was 2.7 years
(SD 4.1 years, range 0.1–35.5 years). The second tumor that
necessitated STL was considered a residual tumor after organ
preserving treatment in 40.2% of cases (n= 162), local recurrence
of the initial tumor in 40.5% of cases (n = 163), and a second
primary carcinoma in 19.4% of cases (n = 78). The glottis
was, again, the most commonly involved subsite (43.5%). When
compared to the primary tumors, a shift is observed from locally
limited disease for the initial tumor to locally advanced disease
for the second tumor (cT3 and cT4a in 35.9 and 26.8% of cases,
respectively). The majority of second tumors presented without
nodal involvement (cN0 in 84.8% of cases).
Recurrent/residual/second primary tumors were clinically
staged as stage I (n = 33; 8.9%), II (n = 79; 21.2%), III (n = 137;
36.7%), and IV (n = 124; 33.2%). Postoperatively, patients were
most commonly pathologically classified as pT4a (34.8%) and
pN0 (84.9%). Free margins (>5mm) were obtained after STL in
81% (n= 317) of patients.
Treatment Characteristics and
Complications
Details related to the surgical procedure performed are illustrated
in Table 5. One hundred forty-five patients (35.9%) underwent
a STL without pharyngeal resection, while 259 patients (64.1%)
underwent a STL with partial pharyngectomy. Primary closure
of the neopharynx without tissue transfer was performed in 173
patients (43.0%), while in the remainder of patients, a variety
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TABLE 3 | Initial tumor characteristics.
Initial tumor characteristics n %
Histology (n = 398)
Non-squamous cell carcinoma 3 0.75
Squamous cell carcinoma 395 99.25
Clinical tumor classification (n = 401)
Tx 2 0.50
T1 166 41.40
T2 126 31.42
T3 87 21.70
T4a 19 4.74
T4b 1 0.25
Clinical nodal classification (n = 401)
N0 325 81.05
N1 30 7.48
N2 (no further specification) 5 1.25
N2a 7 1.75
N2b 19 4.74
N2c 15 3.74
Clinical metastasis classification (n = 401)
M0 401 100
Overall stage (n = 401)
I 160 39.90
II 103 25.69
III 86 21.45
IVa 51 12.72
IVb 1 0.25
Location (n = 402)
Oropharynx 18 4.48
Hypopharynx 19 4.73
Supraglottic 96 23.88
Glottic 260 64.68
Subglottic 6 1.49
Other head neck site 3 0.75
Treatment initial tumor (n = 403)
Surgery + adjuvant RT 22 5.46
Surgery + adjuvant CRT 6 1.49
Definitive RT 308 76.43
Definitive CRT 57 14.14
Induction chemotherapy + definitive CRT 3 0.74
Induction chemotherapy + definitive RT 1 0.25
Other 6 1.49
RT: total dose larynx (in Gray)
N 325
Mean 66.40
Std 6.715
Median 69.50
IQR (66.00–77.00)
Range (0.00–75.80)
RT: total dose initial tumorsite (in Gray)
N 171
Mean 67.53
Std 3.502
Median 69.12
IQR (66.00–70.00)
Range (50.00–75.80)
TABLE 4 | Secondary tumor characteristics.
Secondary tumor
characteristics
n %
Years prior to second tumor
N 385
Mean 2.70
Std 4.070
Median 1.20
IQR (0.61–2.96)
Range (0.06–35.48)
Type of second tumor (n = 403)
Local recurrence 163 40.45
Second primary 78 19.35
Residual tumor 162 40.20
Initial location second tumor (n = 402)
Hypopharynx 24 5.97
Glottic 175 43.53
Supraglottic 119 29.60
Subglottic 22 5.47
Transglottic 49 12.19
Combination 13 3.23
Clinical tumor classification (n = 373)
Tx 2 0.54
T1 19 5.09
T1a 11 2.95
T1b 15 4.02
T2 89 23.86
T3 134 35.92
T4a 100 26.81
T4b 3 0.80
Clinical nodal classification (n = 376)
N0 319 84.84
N1 25 6.65
N2a 2 0.53
N2b 14 3.72
N2c 10 2.66
N3 6 1.60
Clinical metastasis classification (n = 376)
M0 374 99.47
M1 2 0.53
Pathological tumor classification (n = 388)
Tx 3 0.77
T1 19 4.90
T1a 11 2.84
T1b 17 4.38
T2 75 19.33
T3 123 31.70
T4a 135 34.79
T4b 5 1.29
Pathological nodal classification (n = 391)
N0 332 84.91
N1 22 5.63
N2a 4 1.02
(Continued)
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TABLE 4 | Continued
Secondary tumor
characteristics
n %
N2b 13 3.32
N2c 9 2.30
N3 11 2.81
Overall stage (n = 373)
I 33 8.85
II 79 21.18
III 137 36.73
IVa 113 30.29
IVb 8 2.14
IVc 3 0.80
Section margins (n = 392)
Free margins (>5mm) 317 80.87
Close margin (<5mm) 45 11.48
Positive margin (<5mm) 30 7.65
TABLE 5 | Surgery/procedural characteristics.
Surgery/procedural characteristics n %
Type of salvage operation (n = 404)
Total laryngectomy 145 35.89
Total laryngectomy with partial pharyngectomy 259 64.11
Reconstruction type (n = 402)
None 173 43.03
PM flap muscle onlay 131 32.59
Myocutaneous PM flap 94 23.38
Radial forearm free flap 3 0.75
Other 1 0.25
Extent of neck dissection (n = 400)
None 121 30.25
Ipsilateral 136 34.00
Bilateral 143 35.75
Tracheo-esophageal puncture (n = 368)
None 32 8.70
Primary 320 86.96
Secondary 16 4.35
Adjuvant treatment STL (n = 398)
No adjuvant treatment 380 95.48
Adjuvant RT (reirradation) 14 3.52
Adjuvant CRT (including reirradiation) 2 0.50
Other 2 0.50
of healthy tissue transfer was used with the underlying idea
to minimize postoperative complications. Most commonly used
tissue transfer was onlay PM muscle flap in 131 patients (32.6%)
and inset myocutaneous PM flap in 94 patients (23.4%). The
decision to use tissue transfer for reconstruction depended on the
pharyngeal defect after tumor ablation and was also influenced
by institutional practice/surgeon’s preference. Twenty percent of
patients (n = 48) underwent a total thyroidectomy, while ∼64%
(n= 153) underwent a partial thyroidectomy. Nearly all patients
(95.5%) received definitive STL as a treatment modality without
adjuvant therapies. Eighteen patients (4.5%) underwent adjuvant
treatment, most often re-irradiation, after STL.
Mean and median follow-up were 8.3 and 7.9 years,
respectively (Kaplan–Meier estimate of potential follow-up).
Postoperative complications are illustrated in Table 6. The mean
duration of hospital stay was 21 days (SD 16.3 days, range 8–
162 days). Thirty-six patients (15.1%) had to be readmitted to the
hospital within 1month (“early readmission”), most frequently as
a result of a late PCF development (n = 26). The mean duration
of hospital stay after early readmission was 11 days (SD 9.5 days,
range 2–44 days). Early postoperative complications (clinical
PCF, wound infection, and hemorrhage) occurred in 134 patients
(34.2%): PCF was the most common complication (n = 100,
25.5%) and was conservatively treated in the majority of patients
affected (n = 87, 87%). Postoperative hemorrhage and wound
infections were reported in 21 patients (5.4%) and 63 patients
(16.2%), respectively. One patient (0.3%) died within 30 days
after STL due to the consequences of a myocardial infarction.
The global rate of permanent hypoparathyroidism necessitating
long-term calcium substitution and administration of alfacalcidol
(1-Alpha R© Leo) was 5.4% (20/372) or 35.1% (20/57) in the
subgroup of patients who underwent a total thyroidectomy
during STL. Surgical revision of the tracheostoma, indicated
for narrowed tracheostomas leading to hygienic problems or
breathing discomfort, proved necessary in 1.9% (7/372) of cases
during follow-up.
Relationship Between Esophagram
Results and PCF Formation
Postoperative esophagram results were collected from 234 UZ
Leuven patients with the goal to examine the relationship
between esophagram findings and the presence of or evolution
toward clinical PCF formation. One hundred sixty-eight patients
(71.8%) showed no salivary leakage on their first postoperative
esophagram, while 66 patients (28.2%) did show a neopharyngeal
dehiscence and beginning fistula development. Of these 66
patients, 34 (51.5%) also developed a clinical PCF during the later
postoperative course, while 32 (48.5%) did not. In the group of
168 patients with a satisfactory first postoperative esophagram,
15.5% (n = 26) developed a delayed clinical PCF after start
of oral intake and were eventually readmitted to the hospital.
As such, delayed PCF formation was an important reason for
hospital readmission. Comparing this subgroup of patients with
the subgroup of patients with a satisfactory fluoroscopy who
did not develop a clinical PCF, the former group of patients
underwent significantly more chemoradiation (when compared
to RT alone) as treatment modality for the first tumor (p= 0.026,
Fisher’s exact test). No differences between both groups were
identified in relation to tumor stage, cTNM classification, pTNM
classification, type of salvage operation (TL vs. TL with partial
pharyngectomy), or reconstruction type.
A pharyngeal dehiscence observed on esophageal fluoroscopy
without presence of a (clinical) PCF can be considered a
“subclinical PCF.” When both clinical and subclinical fistulas
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TABLE 6 | Complications and functional outcomes.
Postoperative complications n % Functional results n %
Hospital stay STL (days) Days to resume peroral feeding
N 394 N 328
Mean 21.34 Mean 19.88
Std 16.272 Std 25.795
Median 16.00 Median 12.00
IQR (14.00–22.00) IQR (10.00–19.00)
Range (8.00–162.00) Range (4.00–253.00)
Early readmission (n = 238) Achievement total peroral intake (n = 362)
No 202 84.87 No 21 5.80
Yes 36 15.13 Yes 341 94.20
Yes, late fistula related 26 10.92 Achievement functional speech (n = 352)
Yes, stoma related 1 0.42 No 47 13.35
Yes, feeding related 1 0.42 Yes 305 86.65
Yes, infection related
Yes, general health
4
4
1.68
1.68
Type speech (n = 341)
Esophagus speech 11 3.23
Duration early readmission (days) TEP speech 321 94.13
N 36 Electrolarynx speech 9 2.64
Mean 11.08 Permanent tube feeding (n = 363)
Std 9.464 No 343 94.49
Median 8.50 Yes 20 5.51
IQR (4.00–15.00) Dysphagia (n = 351)
Range (2.00–44.00) No 241 68.66
Salivary leakage* (n = 234) Yes 110 31.34
No 168 71.79 Dysphagia treatment (n = 110)
Yes 66 28.21 No treatment 82 74.55
Early complication (PCF, hemorrhage,
wound infection) (n = 392)
Endoscopic dilatation
Neopharyngeal reconstruction
26
2
23.64
1.82
No 258 65.82
Yes 134 34.18
Pharyngocutaneous fistula (n = 392)
No 292 74.49
Yes 100 25.51
Fistula treatment (n = 100)
Conservative therapy 87 87.00
Surgical closure with flap 12 12.00
Surgical revision 1 1.00
Hemorrhage (n = 390)
No 369 94.62
Yes 21 5.38
Wound infection (n = 390)
No 327 83.85
Yes 63 16.15
*Salivary leakage first postoperative gastrografin esophagram.
(data of the latter were only available for UZ Leuven patients)
were taken into account, the “overall PCF” incidence in UZ
Leuven was 40.3% (96/238).
Functional Outcomes
Functional outcomes are illustrated in Table 6. Eventual
complete oral intake was achieved in 341 patients (94.2%). The
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mean and median time intervals between STL and resumption
of peroral feeding were 19.9 and 12.0 days, respectively (SD
25.8 days, range 4–253 days). Twenty patients (5.5%) remained
long-term tube feeding-dependent (G-tube or jejunostomy).
Postoperative dysphagia, as subjectively reported by the patients
during follow-up, proved a common complaint and occurred in
110 patients (31.3%), but did not require any treatment in most
cases (n = 82, 74.6%) because of the mild severity. In more
serious cases of dysphagia with an impact on peroral intake,
surgical management of neopharyngeal stenosis by endoscopic
dilations (Savary or balloon dilations, n = 26 or 7.4%) or
neopharyngeal reconstruction (n = 2 or 0.6%) proved necessary.
Regarding speech rehabilitation, 86.7% of patients (n = 305)
achieved a functional speech, which was most frequently
achieved by TEP speech (94.1%). In total, 90.7% of TEP patients
achieved functional speech. Primary TEP (during STL) was
performed in 320 patients (86.7%), of whom 90.3% achieved
functional speech, while secondary puncture was performed in
only 16 cases (4.4%), of whom 100% achieved functional speech.
Factors Predictive for Early Postoperative
Complications and PCF Formation
Treating center, preoperative Hb, postoperative Hb, and
treatment modality of the initial/primary tumor were
significantly associated with overall postoperative complication
rates (including PCF, postoperative bleeding, and infection)
upon univariable analysis, with lower Hb levels (<12.5 g/dl) and
chemoradiation (when compared to RT alone) increasing the
probability for a complicated postoperative course. However,
only preoperative Hb remained a significant prognostic factor
in multivariable analysis (OR = 0.579, p = 0.0241). Minor
but significant differences were seen in overall complication
rate between participating centers (ranging from 11.1% to
40.6%, p = 0.021 on Fisher’s exact test) and treatment center
was identified as a prognostic factor for complication rate
(p = 0.0463) on univariable analysis. However, after correcting
for potential confounders (cT, cN, pT, pN, tumor stage, type of
salvage operation, and reconstruction type), the treatment center
could not be confirmed as a significant risk factor for overall
complication rate (p= 0.19).
No significant prognosticators for clinical PCF formation
specifically were identified, neither on univariable nor on
multivariable analysis. Clinical PCF incidence proved
comparable among centers (ranging from 11.11 to 37.50%,
p = 0.142 on Fisher’s exact test). Table 1 lists the results of
univariable analysis. No confounding factors were identified.
However, when performing univariable analysis in the subgroup
of patients from 1 center (UZ Leuven) with clinical and
subclinical PCFs taken together (“overall PCF”), higher
preoperative hemoglobin (>12.5 g/dl) (OR= 0.55, p= 0.03) and
reconstruction with an onlay PM flap when compared to no flap
(OR = 0.50, p = 0.04) or to myocutaneous PM flap (OR = 0.31,
p < 0.01) were associated with a lower probability of (clinical
or subclinical) fistula formation, while chemoradiation as a
treatment of the first tumor (when compared to RT; OR = 3.15,
p < 0.01) was identified as a negative prognosticator for overall
fistula formation. On multivariable analysis, the use of a PM
muscle onlay was confirmed to have a protective effect in
preventing overall fistula formation when compared to no PM
flap (OR = 0.36, p < 0.01) or inset myocutaneous PM flap
(OR = 0.29, p < 0.01), while the negative prognostic effect
of prior radiochemotherapy (OR = 3.77, p ≤ 0.01) could also
be confirmed.
Factors Predictive for Functional
Outcomes
Non-achievement of Peroral Intake
Tables 7, 8 show the uni- and multivariable analysis of variables
potentially related to non-achievement of total peroral intake.
cN classification of the second tumor was identified as a
possible confounder and this was corrected for in the analysis.
Reconstruction type, treatment of the initial tumor, development
of postoperative complications in general and PCF in particular
and section margin status all proved significantly associated with
non-achievement of total peroral intake on univariable analysis.
The use of an onlay PM muscle flap or inset myocutaneous
PM flap was significantly associated with a lower probability
of achieving total peroral intake when compared to primary
neopharyngeal closure without tissue transfer (p = 0.0057,
and p = 0.0122, respectively). Section margin status proved
to have a significant prognostic impact with non-achievement
of total peroral intake being less likely when free margins
could be obtained (p < 0.01). In the subgroup of patients
with a residual or recurrent tumor, primary treatment by
surgery and adjuvant RT proved a negative prognostic factor
(p= 0.0249). Uponmultivariable analysis, treatment of the initial
tumor, PCF formation during the postoperative period, and free
margin status remained significant prognosticators. Patients who
postoperatively developed a PCF were less likely to eventually
achieve total peroral intake (OR= 4.5, p= 0.0052), while patients
with a free section margin status were more likely to achieve
total peroral intake (OR = 0.179, p = 0.0132). Multivariable
analysis applied to the subgroup with residual/recurrent tumors
confirmed the negative impact of surgical treatment with
adjuvant RT for the first tumor as compared to definitive
RT (OR = 11.8, p = 0.0134). Definite CRT (compared to
definitive RT) showed a trend toward worse outcome in the
recurrent/residual group (OR=3.5, p = 0.0975) and in the total
group (OR = 3.0, p = 0.0854). When applied to the subgroup
with second primary tumors, no significant impact of treatment
modality of the first tumor could be identified.
Permanent Tube Feeding
Table 9 shows the uni- and multivariable analysis of variables
potentially related to postoperative permanent tube feeding. cN
classification of the second tumor was again identified as a
possible confounder; this was corrected for in analysis. Patients
who experienced postoperative complications in general and PCF
formation in particular were significantly more likely to stay
tube feeding-dependent upon univariable analysis (OR = 3.5,
p = 0.011 and OR = 3.7, p = 0.0062, respectively). Patients
with free section margins were less likely to remain G-tube
dependent (OR = 0.3, p = 0.044). Upon multivariable analysis,
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TABLE 7 | Prognostic factors for non-achievement total peroral intake with correction for confounding (univariable).
Variables Univariable Prognostic factors
OR 95% CI p-value
Type of salvage operation
STL+partial pharyngectomy vs. STL 2.567 0.668–9.860 0.1698
Reconstruction type
Global test 0.0179
PM flap muscle onlay vs. myocutaneous PM flap 1.051 0.370–2.983 0.9256
PM flap muscle onlay vs. none 7.577 1.803–31.851 0.0057
Myocutaneous PM flap vs. none 7.210 1.539–33.776 0.0122
Type of second tumor
Global test 0.2222
Local recurrence vs. Residual tumor 0.442 0.132–1.478 0.1849
Local recurrence vs. Second primary 0.316 0.084–1.186 0.0877
Residual tumor vs. Second primary 0.716 0.243–2.107 0.5443
Treatment initial tumor (residual/recurrent)
Surgery + adjuvant RT vs. definitive CRT 2.791 0.309–25.178 0.3603
Surgery + adjuvant RT vs. definitive RT 9.592 1.331–69.147 0.0249
Definitive CRT vs. definitive RT 3.436 0.883–13.377 0.0750
Treatment initial tumor (second primary)
Surgery + adjuvant RT vs. definitive CRT 1.503 0.136–16.605 0.7398
Surgery + adjuvant RT vs. definitive RT 7.218 0.820–63.547 0.0749
Definitive CRT vs. definitive RT 4.804 0.508–45.391 0.1708
Radiotherapy initial tumor dose on larynx (Gray)
+ 1 unit 1.080 0.954–1.224 0.2251
Tracheo-esophageal puncture
Secondary/none vs. Primary 0.261 0.052–1.316 0.1036
Adjuvant treatment STL
Yes (any type) vs. No 0.974 0.116–8.163 0.9809
Complication (any type)
Yes (any type) vs. No 2.482 1.003–6.141 0.0492
Section Margins
Free (>5mm) vs. positive 0.119 0.037–0.384 0.0004
Pharyngocutaneous Fistula STL
Yes (any type) vs. No 3.398 1.361–8.485 0.0088
Binary variables/pairwise tests: OR > (<) 1: higher (lower) risk for first category. Reconstruction type: radial forearm free flap (n= 3) and other (n= 1) excluded. Bold values are statistically
significant (p < 0.05).
TABLE 8 | Prognostic factors for non-achievement total peroral intake (multivariable analysis).
Variables Multivariable Prognostic factors all tumors Multivariable Prognostic factors residual/recurrent tumors
OR 95% CI p-value OR 95% CI p-value
Treatment initial tumor
Global test 0.0038 0.0712
Surgery + adjuvant RT vs. definitive CRT 4.050 0.916–17.910 0.0651 3.365 0.423–26.741 0.2513
Surgery + adjuvant RT vs. definitive RT 12.159 3.159–46.798 0.0003 11.845 1.668–84.109 0.0134
Definitive CRT vs. definitive RT 3.002 0.858–10.502 0.0854 3.520 0.794–15.600 0.0975
Section margins
Free (>5mm) vs. positive 0.179 0.046–0.698 0.0132 0.396 0.062–2.541 0.3284
Pharyngocutaneous Fistula STL
Yes (any type) vs. No 4.511 1.567–12.984 0.0052 5.676 1.532–21.031 0.0094
Binary variables/pairwise tests: OR > (<) 1: higher (lower) risk for first category. Reconstruction type: radial forearm free flap (n= 3) and other (n= 1) excluded. Bold values are statistically
significant (p < 0.05).
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TABLE 9 | Prognostic factors for permanent tube feeding with correction for confounding.
Variables Univariable Prognostic factors Multivariable Prognostic factors
OR 95% CI p-value OR 95% CI p-value
Type of salvage operation
STL+partial pharyngectomy vs. STL 0.777 0.263–2.300 0.6488 -
Reconstruction type
PM flap muscle onlay vs. myocutaneous PM flap 1.183 0.362–3.864 0.7803 -
PM flap muscle onlay vs. none 2.122 0.660–6.829 0.2069 -
Myocutaneous PM flap vs. none 1.793 0.474–6.792 0.3899 -
Type of second tumor
Local recurrence vs. Residual tumor 0.756 0.232–2.462 0.6428 -
Local recurrence vs. Second primary 0.404 0.115–1.416 0.1567 -
Residual tumor vs. Second primary 0.534 0.172–1.660 0.2782 -
Treatment initial tumor (residual/recurrent)*
Surgery + adjuvant RT vs. definitive CRT 0.643 0.039–10.587 0.7577 -
Surgery + adjuvant RT vs. definitive RT 2.369 0.187–29.954 0.5052 -
Definitive CRT vs. definitive RT 3.682 0.918–14.770 0.0659 -
Treatment initial tumor (second primary)*
definitive CRT vs. definitive RT 3.631 0.442–29.854 0.2303 -
Radiotherapy initial tumor dose on larynx (Gray)
+1 unit 1.053 0.935–1.187 0.3908 -
Tracheo-oesofageal puncture*
Primary vs. secondary 0.625 0.075–5.232 0.6646 -
Adjuvant treatment STL
Yes (any type) vs. No 2.438 0.483–12.305 0.2805 -
Complication (any type)
Yes vs. No 3.477 1.330– 9.088 0.0110 -
Section margins
Free (>5mm) vs. positive 0.279 0.080–0.966 0.0440 -
Pharyngocutaneous Fistula STL
Yes vs. No 3.739 1.454–9.615 0.0062 3.739 1.454–9.615 0.0062
Clinical nodal stage second tumor
+1 level - 1.371 1.051–1.788 0.0198
Binary variables/pairwise tests: OR > (<) 1: higher (lower) risk for first category. Reconstruction type: radial forearm free flap (n = 3) and other (n = 1) excluded.
*Not all pairwise comparisons were estimable due to small groups/zero events.
Bold values are statistically significant (p < 0.05).
PCF and higher cN classification of the second tumor were
identified as independent prognostic factors for long-term tube
feeding dependency (OR = 3.7, p = 0.0062 and OR = 1.4,
p= 0.0198, respectively).
Post-operative Dysphagia
Table 10 depicts the uni- and multivariable analysis of variables
potentially related to postoperative dysphagia. No confounders
could be identified. Upon univariable analysis, development
of postoperative complications and PCF, TL with partial
pharyngectomy (compared to TL alone) and reconstruction with
an onlay PMmuscle flap (when compared to inset myocutaneous
PM flap and to no tissue transfer) proved significant risk
factors for postoperative dysphagia. The prognostic effect of
the reconstruction modality was re-assessed in the subgroup of
patients undergoing a TL without partial pharyngectomy and
the negative impact of a muscle onlay PM flap on dysphagia,
when compared to no tissue transfer, was confirmed in this
subgroup (OR = 3.9, p = 0.0097). However, when the use
of an inset myocutaneous PM flap was compared to the
onlay muscle PM in the TL without partial pharyngectomy
subgroup, the onlay PM flap did lose its negative prognostic
effect on postoperative dysphagia (OR = 3.7, p = 0.2519). In
the subgroup of patients who underwent STL for residual or
recurrent tumors, treatment of the initial tumor proved to be
an additional prognostic factor. Patients who underwent surgery
combined with adjuvant RT as treatment of the initial tumor were
more likely to experience postoperative dysphagia compared
to definitive RT.
Upon multivariable analysis, type of salvage operation,
reconstruction type, and postoperative PCF remained
significant. Patients who developed PCF postoperatively
were 2.4 times more likely to experience postoperative dysphagia
compared to those without PCF (p = 0.0010). Dysphagia
was 2.7 times less likely in patients treated only with TL
compared to those who also underwent a partial pharyngectomy
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TABLE 10 | Prognostic factors for postoperative dysphagia, in the total patient group and in the salvage total laryngectomy without pharyngectomy [TL] subgroup.
Variables Univariable Prognostic factors Multivariable Prognostic factors
OR 95% CI p-value OR 95% CI p-value
Type of salvage operation
STL+partial pharyngectomy vs. STL 2.680 1.559–4.607 0.0004 2.661 1.469–4.819 0.0012
Reconstruction type
PM flap muscle onlay vs. myocutaneous PM flap 2.061 1.130–3.760 0.0183 2.527 1.350–4.728 0.0037
PM flap muscle onlay vs. myocutaneous PM flap
[TL]
3.684 0.396–34.291 0.2519 -
PM flap muscle onlay vs. none 2.932 1.711–5.025 <0.0001 2.716 1.536–4.803 0.0006
PM flap muscle onlay vs. none [TL] 3.918 1.392–11.026 0.0097 -
Myocutaneous PM flap vs. none 1.422 0.779–2.596 0.2512 1.075 0.564–2.048 0.8257
Myocutaneous PM flap vs. none [TL] 1.063 0.117–9.673 0.9564 -
Type of second tumor
Local recurrence vs. Residual tumor 0.906 0.545–1.507 0.7046 -
Local recurrence vs. Second primary 0.813 0.441–1.499 0.5073 -
Residual tumor vs. Second primary 0.897 0.488–1.651 0.7272 -
Treatment initial tumor (residual/recurrent)
Surgery + adjuvant RT vs. definitive CRT 3.176 0.700;- 14.421 0.1343 -
Surgery + adjuvant RT vs. definitive RT 4.951 1.200–20.430 0.0270 -
Surgery + adjuvant RT vs. surgery + adjuvant CRT 6.000 0.422–85.248 0.1857 -
Definitive CRT vs. definitive RT 1.559 0.793–3.063 0.1980 -
Definitive CRT vs. surgery + adjuvant CRT 1.889 0.181–19.670 0.5947 -
Definitive RT vs. surgery + adjuvant CRT 1.212 0.124–11.880 0.8689 -
Treatment initial tumor (second primary)*
Surgery + adjuvant RT vs. definitive CRT 1.875 0.302–11.626 0.4995 -
Surgery + adjuvant RT vs. definitive RT 2.833 0.666–12.059 0.1587 -
definitive CRT vs. definitive RT 1.511 0.371–6.149 0.5642 -
Radiotherapy initial tumor dose on larynx (Gray)
+1 unit 1.025 0.982–1.070 0.2556 -
Tracheo-oesofageal puncture*
Primary vs. secondary 3.015 0.662–13.727 0.1537 -
Adjuvant treatment STL
Yes (any type) vs. No 0.280 0.063–1.248 0.0952 -
Complication (any type)
Yes vs. No 2.026 1.273–3.225 0.0029 -
Section margins
Free (>5mm) vs. positive 0.952 0.416–2.181 0.9081 -
Pharyngocutaneous Fistula STL
Yes vs. No 2.179 1.328–3.575 0.0021 2.406 1.424–4.065 0.0010
Binary variables/pairwise tests: OR > (<) 1: higher (lower) risk for first category. Reconstruction type: radial forearm free flap (n = 3) and other (n = 1) excluded.
*Not all pairwise comparisons were estimable due to small groups/zero events.
Bold values are statistically significant (p < 0.05).
(p= 0.0012). Reconstruction with a muscle onlay PM flap proved
independently associated with more dysphagia when compared
to inset myocutaneous PM flap (OR = 2.5, p = 0.0037)
and to primary closure without tissue transfer (OR = 2.7,
p = 0.0006). However, upon multivariable analysis of the “total
laryngectomy alone subgroup,” the reconstruction type lost its
prognostic effect.
Non-achievement of Functional Speech
Upon univariable analysis, the total dose of administered RT
on the larynx during irradiation of the primary tumor was
identified as a continuous variable, which was significantly
associated with the non-achievement of functional speech
during the postoperative course, with higher doses implying
higher risk for non-achievement of functional speech.
However, the administered dose of RT on the larynx lost
its prognostic significance after correcting for pN classification
as a confounder. Additionally, an effect of margin status on
non-achievement of functional speech was observed, with free
margins acting as a negative prognosticator for non-achievement
of functional speech/positive prognosticator for functional
speech (OR = 0.192, p < 0.01). Multivariable analysis confirmed
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TABLE 11 | Prognostic factors for non-achievement functional speech with correction for confounding (univariable).
Variables Prognostic factors
OR 95% CI p-value
Type of salvage operation
STL+partial pharyngectomy vs. STL 0.839 0.431–1.635 0.6068
Reconstruction type
PM flap muscle onlay vs. myocutaneous PM flap 1.378 0.579–3.281 0.4683
PM flap muscle onlay vs. none 1.175 0.567–2.432 0.6644
Myocutaneous PM flap vs. none 0.852 0.369–1.970 0.7085
Type of second tumor
Local recurrence vs. Residual tumor 1.491 0.713–3.118 0.2891
Local recurrence vs. Second primary 1.414 0.578–3.460 0.4475
Residual tumor vs. Second primary 0.949 0.385–2.340 0.9092
Treatment initial tumor (residual/recurrent)
Surgery + adjuvant RT vs. definitive CRT 1.140 0.115–11.334 0.9107
Surgery + adjuvant RT vs. definitive RT 1.332 0.153–11.578 0.7950
Definitive CRT vs. definitive RT 1.168 0.442–3.088 0.7544
Treatment initial tumor (second primary)
Surgery + adjuvant RT vs. definitive CRT 0.789 0.079–7.929 0.8405
Surgery + adjuvant RT vs. definitive RT 2.267 0.337–15.226 0.3998
definitive CRT vs. definitive RT 2.872 0.430–19.181 0.2761
Radiotherapy initial tumor dose on larynx (Gray)
+1 unit 1.067 0.990–1.149 0.0887
Adjuvant treatment STL
Yes (any type) vs. No 1.787 0.488–6.542 0.3809
Complication (any type)
Yes vs. No 1.176 0.614–2.252 0.6247
Section Margins
Free (>5mm) vs. positive 0.192 0.078–0.471 0.0003
Pharyngocutaneous Fistula STL
Yes vs. No 1.311 0.655–2.624 0.4451
Continuous variables: OR > (<) 1: increased (decreased) risk with increasing variable level. Binary variables/pairwise tests: OR > (<) 1: higher (lower) risk for first category.
Reconstruction type: radial forearm free flap (n = 3) and other (n = 1) excluded.
Bold values are statistically significant (p < 0.05).
this independent prognostic effect of section margin status
(OR = 0.175, p < 0.01) and identified pT classification as an
additional prognosticator with higher pT classifications related
to a higher chance of not achieving functional speech (OR= 1.45,
p < 0.01). Table 11 shows the univariable analysis of variables
potentially related to non-achievement of functional speech,
with correction for confounding factors.
Prognostic Factors for Hospital Stay
Duration
Multiple significant prognostic factors were identified for
hospital stay duration upon univariable analysis and are listed
in Table 12. Upon multivariable analysis, myocutaneous PM
flap reconstruction was significantly associated with longer
hospital stay. Patients who underwent myocutaneous PM flap
reconstruction had a 30.5% increase in hospital stay compared
to patients who had no flap reconstruction (relative effect or
RE = 1.305, p ≤ 0.0001); the latter had a 21.1% increase
compared to PM flap muscle onlay patients (RE = 0.789, p
≤ 0.0001). Patients without TEP stayed longer in the hospital
compared to those who underwent a primary or secondary
TEP (15.9 and 36.7% increase respectively). This finding most
likely represents a selection bias to the fact that the decision
to refrain from TEP is preferentially made in patients with
significant comorbidities, and/or poor tissue quality, making
themmore susceptible to postoperative complications and longer
hospital stay. Postoperative complications (any) and clinical PCF
prolonged hospitalization by 41.5% (RE= 1.415; p≤ 0.0001) and
24.6% (RE= 1.246; p= 0.0030), respectively.
DISCUSSION
Surgical complications prolong the length of hospital stay,
negatively impact healthcare and costs, and delay initiation
of peroral feeding and rehabilitation, consequently worsening
global outcomes. Complication rate is higher in salvage patients,
due to the prior radiation’s effect on the tissue’s microvasculature
and healing capacities (11, 13). We report a complication
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TABLE 12 | Prognostic factors for hospital stay.
Variables Univariable Prognostic factors Multivariable Prognostic factors
RE 95% CI p-value RE 95% CI p-value
Type of second tumor
Local recurrence vs. Residual tumor 0.897 0.811–0.992 0.0340 -
Local recurrence vs. Second primary 0.843 0.744–0.956 0.0078 -
Residual tumor vs. Second primary 0.940 0.829–1.067 0.3390 -
Initial location second tumor
Combination vs. glottic 1.041 0.798–1.357 0.7694 -
Combination vs. hypopharynx 0.697 0.507–0.960 0.0269 -
Combination vs. subglottic 1.051 0.764–1.447 0.7596 -
Combination vs. supraglottic 1.017 0.777–1.332 0.9013 -
Combination vs. transglottic 1.041 0.781–1.388 0.7826 -
Glottic vs. hypopharynx 0.670 0.548–0.820 <0.0001 -
Glottic vs. subglottic 1.010 0.826–1.236 0.9215 -
Glottic vs. supraglottic 0.978 0.878–1.088 0.6783 -
Glottic vs. transglottic 1.001 0.865–1.157 0.9925 -
Hypopharynx vs. subglottic 1.508 1.153–1.972 0.0027 -
Hypopharynx vs. supraglottic 1.459 1.186–1.795 0.0003 -
Hypopharynx vs. transglottic 1.493 1.188–1.878 0.0006 -
Subglottic vs. supraglottic 0.968 0.787–1.190 0.7563 -
Subglottic vs. transglottic 0.991 0.788–1.246 0.9357 -
Supraglottic vs. transglottic 1.024 0.878–1.193 0.7647 -
Pathological tumor classification second tumor
+1 level 0.992 0.960–1.026 0.6508 -
Pathological nodal classification second tumor
+1 level 1.032 0.999–1.066 0.0575 -
Overall tumor stage second tumor
+1 level 1.063 1.016–1.112 0.0082 -
Preoperative active smoking
Yes vs. No 1.041 0.933–1.161 0.4695 -
Preoperative tracheotomy
Yes vs. No 1.128 0.959–1.327 0.1444 -
Extent of neck dissection
Bilateral vs. Ipsilateral 0.996 0.890–1.115 0.9461 -
Bilateral vs. None 1.034 0.919–1.163 0.5822 -
Ipsilateral vs. None 1.038 0.921–1.169 0.5427 -
Section margins second tumor
Close margin (<5mm) vs. Free margins (>5mm) 1.150 0.996–1.328 0.0569 -
Close margin (<5mm) vs. Positive margin 1.168 0.943–1.446 0.1551 -
Free margins (>5mm) vs. Positive margin 1.015 0.854–1.208 0.8640 -
Preoperative Hb
≥12.5 g/dl vs. <12.5 g/dl 0.914 0.825–1.012 0.0830 -
Postoperative Hb
≥12.5 g/dl vs. <12.5 g/dl 0.797 0.711–0.894 0.0001 -
Preoperative albumin
≥3.5 g/dl vs. <3.5 g/dl 0.953 0.787–1.153 0.6177 -
Postoperative albumin
≥3.5 g/dl vs. <3.5 g/dl 0.901 0.743–1.093 0.2901 -
Type of salvage operation
STL+partial pharyngectomy vs. STL 1.023 0.926–1.129 0.6542 0.916 0.839–0.999 0.0475
Reconstruction type
(Continued)
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TABLE 12 | Continued
Variables Univariable Prognostic factors Multivariable Prognostic factors
RE 95% CI p-value RE 95% CI p-value
PM flap muscle onlay vs. myocutaneous PM flap 0.808 0.713–0.915 0.0008 0.789 0.713–0.873 <0.0001
PM flap muscle onlay vs. none 1.052 0.944–1.171 0.3593 1.030 0.939–1.130 0.5277
Myocutaneous PM flap vs. none 1.301 1.156–1.464 <0.0001 1.305 1.178–1.446 <0.0001
Treatment initial tumor (residual/recurrent)
Surgery + adjuvant RT vs. definitive CRT 1.017 0.740–1.399 0.9166 -
Surgery + adjuvant RT vs. definitive RT 1.095 0.814–1.473 0.5507 -
Surgery + adjuvant RT vs. surgery + adjuvant CRT 0.995 0.611–1.619 0.9823 -
Definitive CRT vs. definitive RT 1.076 0.935–1.238 0.3064 -
Definitive CRT vs. surgery + adjuvant CRT 0.978 0.648–1.476 0.9145 -
Definitive RT vs. surgery + adjuvant CRT 0.909 0.612–1.349 0.6343 -
Treatment initial tumor (second primary)
Surgery + adjuvant RT vs. definitive CRT 0.788 0.511–1.217 0.2825 -
Surgery + adjuvant RT vs. definitive RT 1.079 0.772–1.507 0.6578 -
Surgery + adjuvant RT vs. surgery + adjuvant CRT 1.562 0.564–4.324 0.3907 -
Definitive CRT vs. definitive RT 1.368 0.979–1.912 0.0662 -
Definitive CRT vs. surgery + adjuvant CRT 1.982 0.716–5.486 0.1880 -
Definitive RT vs. surgery + adjuvant CRT 1.448 0.544–3.858 0.4589 -
Radiotherapy initial tumor dose on larynx (Gray)
+1 unit 0.992 0.984–1.000 0.0491 0.990 0.984–0.996 0.0021
Tracheo-oesofageal puncture
None vs. primary 1.208 1.009–1.446 0.0394 1.159 1.004–1.339 0.0441
None vs. secondary 1.256 0.939–1.681 0.1247 1.367 1.081–1.727 0.0089
Primary vs. secondary 1.040 0.817–1.324 0.7499 1.179 0.973–1.428 0.0936
Complication (any type)
Yes vs. No 1.673 1.535–1.825 <0.0001 1.415 1.238–1.616 <0.0001
Pharyngocutaneous Fistula STL
Yes vs. No 1.701 1.545–1.874 <0.0001 1.246 1.078–1.442 0.0030
Continuous variables: RE > (<) 1: increased (decreased) hospital stay with increasing variable level. Binary variables/pairwise tests: RE > (<) 1: longer (shorter) hospital stay for
first category.
e.g., RE = 1.10 means 10% increase.
Reconstruction type: radial forearm free flap (n = 3) and other (n = 1) excluded.
Bold values are statistically significant (p < 0.05).
rate of 34.2% after STL, including clinical PCF formation,
postoperative bleeding, and infection. Overall complication
rates are difficult to compare with previous studies because of
heterogeneity of the population studied and the specification
of complication types included in the analysis. Similar to our
definition, several studies defined postoperative bleeding as
wound hematoma requiring surgical revision (25–27). Furuta
et al. reported postoperative hemorrhages in 5.8% (n = 5)
of their STL patients, which is comparable to our rate of
5.4% (n = 21) (27). Individual studies have reported wound
infection rates between 0.8 and 45% (28, 29). In our series,
local wound infection occurred in 16.15% (n = 63) of the
patients. However, local wound infection in previous studies
was not clearly defined and patient population was not uniform
regarding applied surgical techniques and postoperative care.
With a rate of 25.5%, clinical PCF formation was the most
frequent complication after STL in our series, which is similar
compared to the reported PCF pooled incidence in a recent
systematic review (28.9%) (14). However, when both clinical
and subclinical fistulas were taken into account upon subset
analysis, the “overall PCF” incidence raised to 40.3%. Given the
high rates of complications and their association with significant
morbidity, it is highly relevant to identify potential risk factors for
overall complications and clinical PCF formation in particular.
In univariable analysis, low preoperative hemoglobin (Hb),
low postoperative Hb, and treatment of the primary tumor
by CRT (compared to RT) were significantly associated with
higher overall postoperative complication rates. In previous
studies, prior CRT proved, parallel to our findings, to be related
with higher complication rates (2, 10, 13, 30–33). Possible
explanations for this finding include the more extended toxic
effect on tissues by CRT compared to RT alone and the higher
probability of impaired nutritional and immune status in patients
receiving additional chemotherapy. Finally, CRT is indicated
in patients diagnosed with higher staged tumors, resulting in
an important selection bias of the patients treated with CRT
(1, 7, 34). However, in multivariable analysis, only preoperative
hemoglobin (≥12.5 g/dl) proved to be a significant positive
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prognosticator related to a decreased overall postoperative
complication rate.
No significant risk factors for clinical PCF formation
specifically could be identified, on univariable or onmultivariable
analysis. However, univariable analysis did show a strong trend
toward significance with a negative effect of low postoperative
Hb value (<12.5 g/dl) (p = 0.055), which is not surprising
given the fact that postoperative anemia is known to be
associated with worse healing capacities (35). Primary TEP could
not be identified as a risk factor for PCF formation in this
study, confirming once more the safety of primary TEP in
patients undergoing STL (36). Quite surprising, vascularized
flap tissue reconstruction was not confirmed to be a significant
factor preventing PCF formation, which is in line with various
previously published results (16, 31, 37–42). In a study by
Benson et al., PCF rates even increased when PM coverage was
used (43). However, an inherent selection bias must be taken
into account: more advanced carcinomas are more likely to
undergo flap reconstruction using PMflaps or free tissue transfer.
Nevertheless, tumor stage was not identified as a confounding
factor in our analysis. Other publications however have shown
a protective effect. Two recent systematic reviews examined
the impact of vascularized tissue transfers on reducing fistula
following STL (12, 44). Patel et al. reported a study population of
359 STL patients from eight institutions and observed decreased
fistula rates when either free tissue transfer (25% PCF rate)
or PM overlay (15% PCF rate) was used, as compared to
primary closure (34% PCF rate) (44). Paleri et al. included
seven studies (591 patients) in a systematic review and found
similar results to Patel et al.: they found that fistula formation
was reduced by roughly one-third in patients who underwent
vascularized flap reconstruction (22.2%) compared to those
who underwent primary closure (31.2%) (12). The principle
behind vascularized flap reconstruction is that it will improve
wound healing and prevent fistula formation by using non-
irradiated, well-vascularized tissue. These contradicting findings
described in the literature result in unclarities as to the ideal
method of reconstruction during STL in order to reduce PCF
incidence. Although no significant risk factors for clinical PCF
formation could be identified in the total population, when
repeating univariable analysis in a subgroup of patients from
one center with clinical and subclinical PCFs taken together
(“overall PCF”), higher preoperative hemoglobin (>12.5 g/dl)
and onlay PM flap (when compared to no flap or myocutaneous
PM flap) were associated with less fistula formation, while
chemoradiation as a treatment of the first tumor (when compared
to RT), was identified as a negative prognosticator for overall
fistula formation. On multivariable analysis, the use of a PM
muscle onlay was confirmed to have a protective effect while the
negative prognostic effect of prior radiochemotherapy could also
be confirmed. The inset myocutaneous PM flap’s inferiority in
preventing overall fistula formation can potentially be explained
by the long skin-pharyngeal mucosa suture line when compared
to the shorter classic T-closure of the neopharynx in case of onlay
PM flap reconstruction.
We also examined the relation between findings on the first
postoperative esophagram/esophageal fluoroscopy and evolution
to clinical PCF formation. In our series, salivary leakage on the
first postoperative esophagram was apparent in 28.2% of patients
with approximately half of them eventually developing a clinical
PCF during the later postoperative course. In patients with
a satisfactory first postoperative esophagram, 15% developed
a delayed clinical PCF after start of oral intake, which was
an important reason for hospital readmission. Comparing this
subgroup of patients with the subgroup of patients with a
satisfactory fluoroscopy who did not develop a clinical PCF,
the former group of patients underwent significantly more
chemoradiation (when compared to RT alone) as treatment
modality for the first tumor, suggesting these patients to be at a
higher risk for late PCF development. As a conclusion, a normal
postoperative esophagram did not guarantee an uncomplicated
further evolution and radiographically evident fistulas did not
evolve to clinical apparent fistulas in all cases. The latter finding
can probably be explained by the policy of postponing peroral
feeding after a positive esophagram, potentially preventing
evolution to clinical fistula formation. However, Krouse et al.
found esophagram results to be predictive of, but not preventive
for, PCF formation in patients following (non-salvage) TL (45).
The sensitivity of the esophagram in their study was found to
be 55%, with a specificity of 80%. In another study by White
et al., the sensitivity in salvage patients was only 14%, with a
specificity of 91% (46). The exact reason for the high rate of
patients with a satisfactory esophageal fluoroscopy eventually
developing a clinical PCF is unclear and could be related to
suboptimal sensitivity of the esophageal fluoroscopy using the
aqueous low osmolar contrast agent iopromide (Ultravist R©),
potentially failing to detect small neopharyngeal dehiscences,
which can evolve to a clinical PCF when peroral feeding
is initiated. Although iopromide has fewer side effects while
diagnosing amajor leak (e.g., in case of fistula to the tracheostoma
or trachea), this contrast medium is lighter and penetrates less
as compared to barium. It has been shown that barium has
superior physical properties of mucosal coating and radiographic
density and is better in detecting esophageal perforations when
compared to aqueous contrast media (47). As a consequence,
small defects in the neopharynx might be overlooked during
the Ultravist R© swallow and an additional fluoroscopy using
barium in these patients with a normal Ultravist R© fluoroscopy
could potentially lead to a higher detection rate of subclinical
fistulas, preventing premature restart of oral intake, and as
such, potentially preventing evolution to a clinical PCF. As
we observed a higher proportion of patients who underwent
chemoradiation in the group of patients with normal fluoroscopy
eventually developing a clinical PCF, an additional explanation
for this phenomenon could be related to delayed wound healing
and consequently delayed fistula formation when the watertight
neopharyngeal sutures are absorbing. As a consequence, we
suggest, even after a favorable esophageal fluoroscopy, a slow and
gradual progression in consistencies taken by mouth, especially
in those patients who underwent CRT in the past. We advise our
STL patients to drink clear fluids the first day after the satisfactory
fluoroscopy, followed by liquid and semi-liquid foods for 3 weeks.
Moreover, a first postoperative checkup is scheduled 1 week after
hospital discharge, in order to detect symptoms and signs of late
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PCF formation. Progressive TEP speech rehabilitation, avoiding
high neopharyngeal pressure buildup, is advised during the first
postoperative weeks.
Functional outcomes after STL proved satisfactory in our
series. Most patients in our study eventually achieved total
peroral intake (94.2%; n = 341), which is a higher rate than
reported in a study by van der Putten et al. (84%; n = 94) (28).
However, 31% (n = 110) of our patients reported subjective
dysphagia in the postoperative period, with the majority being
of a mild nature and being managed by conservative measures
(74.6% of cases) such as adjustment of food consistency.
A systematic review by Hasan et al. reported an average
dysphagia rate of 18.6% (incidence 2.9–30.2%), though the
authors highlighted the problem of heterogeneity in dysphagia’s
definition among the included studies (14). In our cohort, single
or serial dilations of neopharyngeal strictures proved necessary
in 23.6% of patients complaining of dysphagia, or in 7.4% of
the total STL population. In a recent paper by Petersen et al.,
assessing dilation incidence after TL, a dilation rate of 20.9% was
observed in the STL group (n = 211). When taking all patients
into account who underwent (C)RT before TL, a dilation rate
of 26.8% was reported. On multivariable analysis, the salvage
setting could not be identified as an independent risk factor for
developing strictures necessitating dilation, but previous (C)RT
was clearly associated with a higher dilation rate (HR = 6.13,
p = 0.003) (48). However, given the discrepancy between patient
populations who underwent previous (C)RT and those who
underwent a STL, it is not quite clear how STL was defined.
In our series, the occurrence of complications and PCF
formation during the postoperative course were identified as
significant risk factors for the non-achievement of peroral
intake, permanent tube feeding, and dysphagia in univariable
analysis. In multivariable analysis, clinical PCF formation
remained an independent risk factor for these swallowing
outcomes. This confirms the findings by Chepeha et al. who
observed that patients who acquired a postoperative fistula
requiring reoperation were ∼3.3 times more likely to have
worse swallowing outcomes. However, PCF that healed without
surgical treatment was not identified as a significant risk
factor (49). Additionally, the reconstruction type significantly
impacted upon various swallowing outcomes in univariable
analysis. Patients undergoing reconstruction with muscle onlay
or myocutaneous PM flaps were significantly less likely to
achieve total peroral intake. However, reconstruction type did
not prove to be a significant and independent prognosticator
in multivariable analysis. The use of vascularized tissue
augmentation has been linked to worse nutritional outcomes in
previous studies, but the impact has so far been understudied
(38, 49, 50). Furthermore, PM muscle onlay reconstruction was
independently associated with more dysphagia when compared
to no tissue transfer or neopharyngeal augmentation with
an inset myocutaneous PM flap. It has been suggested that
the bulkiness of the flap tissue might change swallowing
dynamics of the neopharynx, causing swallowing difficulties
(50). Additionally, these results could be subject to treatment
selection bias by surgeons who are more likely to use flap
reconstruction in more advanced disease necessitating more
advanced resections, as well as in more heavily radiation therapy-
damaged tissue. However, tumor stage was not identified as
a confounding factor in our analysis for dysphagia outcomes,
and both reconstruction type and type of salvage operation
(TL vs. TL with partial pharyngectomy) were independent
prognosticators on multivariable analysis, with dysphagia being
2.66 times more likely in patients treated with TL and partial
pharyngectomy compared to those who only underwent a TL
without pharyngectomy. A recent study by Worley et al. also
observed a progressive increase in stricture rate and resulting
dysphagia with increasing extent of pharyngectomy (51). In
the total patient group (both TL patients and patients with
TL and partial pharyngectomy), reconstruction with a muscle
onlay PM flap proved independently associated with more
dysphagia when compared to inset myocutaneous PM flap
and to primary closure without tissue transfer. Given the
fact that during salvage surgery obtaining free margins is
of the utmost importance, a partial pharyngectomy is often
necessary (64.1% of patients in our population), even in
cases of laryngeal recurrences or laryngeal residual tumors.
Due to our findings of higher dysphagia probability in
patients with muscle onlay PM flaps, regardless its protective
effect for overall (clinical and subclinical) fistula formation,
we would suggest to prefer a myocutaneous inset PM
flap over an onlay PM flap when free tissue transfer is
considered desirable.
Treatment of the initial tumor also proved to have a significant
effect on swallowing outcomes: patients with a residual/recurrent
tumor who underwent surgery combined with adjuvant RT for
their first tumor were less likely to achieve total peroral intake
when compared to RT alone (OR= 11.8).
A high rate of functional speech was observed in this study
(86,5%; n = 305), which is comparable to rates reported in
other publications on STL populations (28, 42). Interestingly,
reconstruction type did not impact voice outcomes in this
study, which is in contrast to findings by Chepeha et al. (49).
The authors did not observe statistically significant differences
in speech outcomes between primary closure and vascularized
tissue augmentation without muscle, but did report worse speech
outcomes in patients with muscle reconstruction. Moreover, our
univariable analysis displayed that patients receiving a higher
dose of RT on the larynx during irradiation of the primary
tumor were less likely to achieve speech rehabilitation and
functional speech, but this effect was lost after correcting for
confounding variables. The possible effect of radiotherapeutic
dose distribution during primary tumor irradiation on speech
outcomes after STL has not been studied so far. A prospective
trial is needed to confirm or reject this potential relation.
Multivariable analysis identified pT classification of the second
tumor as an independent prognostic factor with the higher the
pT classification, the lower the chance of achieving functional
speech. Of interest, a prognostic effect of margin status on non-
achievement of functional speech as well as on non-achievement
of total peroral intake was observed, with free margins acting
as a positive prognosticator for achievement of total peroral
intake and functional speech upon multivariable analysis. This
finding can potentially be explained by the higher probability
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of administering adjuvant re-irradiation to patients with positive
section margins, leading to worse functional outcomes.
There are some limitations in the present study. As the current
study analyzed data retrospectively, selection bias is inherent
to the design. Moreover, we collected data from four different
reference hospitals, and although these hospitals have a similar
general approach and philosophy, there was no standardization
in decision-making or in therapy (e.g., choice of reconstruction
type). Additionally, our study included a heterogeneous group
including residual, recurrent, and second primary tumors with
the first tumor treated by different treatment strategies. Another
drawback of this study is the lack of objective postoperative
functional assessments for speech and swallowing outcomes. As
a result of the multitude of variables, missing data were present
for important secondary endpoints, which might bias the results.
However, our study resulted in a large amount of 405 patients,
which, to our knowledge, is the largest described at the time
of writing this manuscript and the included amount of patients
largely exceeds the sample size of most other published studies.
Thanks to this sample size, a multivariable analysis could be
performed, correcting for confounding, and making the reported
findings more robust and reliable.
CONCLUSION
Substantial complication rates, comparable to the rates described
in the literature, and favorable functional outcomes are
reported after STL. In a multivariable model, lower preoperative
hemoglobin (<12.5 g/dl) was identified as an independent
prognostic factor for higher overall complication rate. No risk
factors were found significant for clinical fistula formation.
Vascularized tissue augmentation did not significantly prevent
clinical PCF. However, when clinical and subclinical PCFs were
taken together (“overall PCF”), the use of a PM muscle onlay
flap was confirmed to have a protective effect while prior
radiochemotherapy was shown to have a negative effect on overall
PCF rate on multivariable analysis. Patients with positive section
margins and patients who developed a PCF or were treated
with surgery combined with adjuvant RT (vs. RT alone) for
their first tumor were less likely to achieve total peroral intake
postoperatively. Postoperative dysphagia proved more likely in
patients who developed a PCF, and less likely in patients who
underwent STL without partial pharyngectomy and in patients
with no or myocutaneous PM flap reconstruction, compared to
muscle onlay PM flap. Achieving postoperative functional speech
proved most likely in patients with smaller tumors (lower pT
classification) and free section margins.
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